November 07, 2024

IHI to pilot novel, applicant-driven approach to next call for proposals

IHI to pilot novel, applicant-driven approach to next call for proposals

While previous IHI calls defined the challenges applicants should address, call 9 will invite applicants to identify untapped opportunities in the IHI Strategic Research and Innovation Agenda.

Key dates and links

10 October: Online info session on the call and the brokerage platform and event – register here

Mid October: Publication of the draft call text on our Future Opportunities page

12-13 November: Face-to-face brokerage event in Brussels, Belgium – register here

14 November: Online meeting rooms made available via brokerage platform for further consortium meetings

Early 2025: Official launch of the call

The brokerage platform will remain open for registration and networking until the call deadline.

Boosting innovation for a competitive European health ecosystem

Until now, the scope of all IHI call topics has been clearly defined in terms of the health challenges to be addressed and the outcomes and impacts expected from the resulting projects. This approach has resulted in a growing portfolio of projects addressing a wide range of disease areas such as cancer, dementia, diabetes and cardiovascular disorders, as well as cross-cutting issues in health research and innovation.

However, there are still untapped opportunities in our IHI Strategic Research and Innovation Agenda (SRIA) for novel ideas on how to harness new science and technologies to foster the development of health innovations.

This is why IHI call 9, which is scheduled for launch in early 2025, has a much broader scope than previous calls, as it will welcome proposals covering any aspect of the SRIA.

“In the past, we told you which challenges we wanted you to work on. This time, we’re turning things around – we want you to tell us what opportunities there are in our SRIA,” explained IHI Executive Director Niklas Blomberg. “If you have a great idea for a public-private partnership, we’d love to hear from you!”

Proposals will still have to adhere to the philosophy of IHI. In other words, they will have to:

  • address an unmet public health need;
  • require a large-scale, ambitious, cross-sector, public-private partnership;
  • have clearly-described impacts on society, the economy and science;
  • take account of the pre-competitive nature of IHI projects.

A standard, single-stage call

From a procedural point of view, IHI call 9 will be a standard, single-stage call for proposals. In practice, this means that applicants will have to ensure that half of their project’s costs are covered by in-kind contributions from IHI’s industry members and (if relevant) IHI contributing partners.

Sign up for our info session and brokerage event

To help potential applicants share ideas and start building a consortium, IHI has set up an online networking platform and will hold a face-to-face brokerage event in Brussels on 12-13 November. In addition to extensive networking time, the event will feature pitches on project ideas and posters from organisations keen to participate in new projects. As a first step, and to tell people more about the call and how to get the most out of the brokerage platform and event, IHI will hold an online info session on 10 October.


Refresher: the IHI SRIA objectives

In their proposal, applicants will have to select the SRIA specific objective that their proposal falls under. Applicants should therefore study the SRIA carefully. Meanwhile, here is a reminder of the titles of the specific objectives in the SRIA:

  1. Improve our understanding of the factors that affect our health and the development and treatment of certain diseases.
  2. Integrate fragmented health research and innovation efforts by bringing together health industry sectors and other stakeholders. This will enable the development of tools, data, platforms, technologies and processes that will in turn facilitate the prevention, diagnosis, treatment and management of diseases, especially in areas where there is an unmet public health need.
  3. Demonstrate the feasibility of integrated healthcare solutions that draw on various technologies from different sectors and address the needs of the people who will use them, such as patients and healthcare professionals.
  4. Make better use of opportunities to gather health data and use it in research and care, all while respecting relevant privacy legislation.
  5. Develop ways of assessing the value of innovative, integrated health care solutions to patients, carers, healthcare professionals and organisations, and other stakeholders.

Read the SRIA in full


Original News

Our latest News

discover more
RHEACELL receives EMA approval for allo-APZ2-CVU Phase 3 trial in chronic venous ulcers

RHEACELL receives EMA approval for allo-APZ2-CVU Phase 3 trial in chronic venous ulcers

Heidelberg, Germany, 19.12.2024 – RHEACELL today received approval from the European Medicines Agency (EMA) for its blinded, multi-centric Phase-3 trial (NCT06489028) evaluating allo-APZ2-CVU in patients with chronic venous ulcers (CVU). The pivotal trial will be conducted at more than 100 sites and is expected to enroll 250 patients, starting enrollment in Europe in Q1 2025. […]

Common cough syrup ingredient shows promise in treating serious lung disease

Common cough syrup ingredient shows promise in treating serious lung disease

EMBL scientists discover that an FDA-approved, over-the-counter cough syrup ingredient has potential to treat fibrotic lung disease. Summary A common over-the-counter ingredient in many cough syrups may have a greater purpose for people suffering from lung fibrosis that is related to any number of serious health conditions.  Scientists from EMBL Heidelberg were part of a […]

Antibody that Neutralizes Inhibitory Factors Involved in Nerve Regeneration Leads to Enhanced Motor Function after Acute Spinal Cord Injury

Antibody that Neutralizes Inhibitory Factors Involved in Nerve Regeneration Leads to Enhanced Motor Function after Acute Spinal Cord Injury

Antibodies can improve the rehabilitation of people with acute spinal cord injury. Researchers at 13 clinics in Germany, Switzerland, the Czech Republic and Spain have investigated this with promising results. For the first time, it was possible to identify patient groups that displayed a clinically relevant treatment effect. A follow-up study will start in December […]

GET IN TOUCH

Stay Updated with bioRN’s Newsletter

Sign up for our newsletter to discover more!
* required

BioRN (BioRN Network e.V. and BioRN Cluster Management GmbH) will use the information you provide on this form to be in touch with you and to provide updates and marketing. Please let us know all the ways you would like to hear from us:

You can update your subscription preferences or unsubscribe at any time. Just follow the unsubscribe or update link in the footer of automated emails you receive from us, or by contacting us at info@biorn.org. We will treat your information with respect. For more information about our privacy practices please visit our website: www.biorn.org. By clicking below, you agree that we may process your information in accordance with these terms.

We use Mailchimp as our marketing platform. By clicking below to subscribe, you acknowledge that your information will be transferred to Mailchimp for processing. Learn more about Mailchimp's privacy practices.

Intuit Mailchimp